Last updated: February 15, 2026
Overview
NDC 64950-0218 is the drug Remdesivir, marketed under the brand name Veklury. It is an antiviral medication approved by the FDA for the treatment of COVID-19 in hospitalized patients. The drug's market dynamics have shifted significantly since its emergency authorization in 2020.
Regulatory Status and Market Entry
- FDA Approval Date: October 22, 2020
- Indication: Treatment of COVID-19 in hospitalized patients requiring supplemental oxygen
- Regulatory extensions: Continued Emergency Use Authorization (EUA) and full approval
- Geographic markets: Primarily U.S., with limited international coverage under individual regulatory decisions
Market Size and Demand
- Global COVID-19 treatments forecast value: Estimated at $20 billion in 2023 (CAGR 5%)
- U.S. demand: Approximately 1 million courses sold annually in 2022; market peaked in 2021 at around 2 million courses due to pandemic surge waves
- Pricing and reimbursement: Medicare, Medicaid, and private insurers reimburse at negotiated rates
Pricing History and Current Estimates
- Original Price (2020): Approximately $520 per vial when Gilead set initial prices for hospitals
- Treatment course: 6 vials, totaling roughly $3,120 per course
- Actual prices vary based on insurer negotiation, hospital contracts, and governmental pricing programs
- Price decline trend: Post-initial surge, prices have stabilized, and Gilead has introduced discounts and access programs to sustain demand
| Price Projections (Next 3-5 years) |
Year |
Estimated Price per Course |
Notes |
| 2023 |
$2,500 - $3,000 |
Stabilized due to contractual negotiations, access programs |
| 2024 |
$2,300 - $2,800 |
Volume-driven discounts increase with broader usage in outpatient setting (less common) |
| 2025 |
$2,000 - $2,500 |
Competition from new antivirals and biosimilars may influence pricing |
Competitive Landscape
- Other COVID-19 antivirals: Paxlovid (Pfizer), Molnupiravir (Merck), which target early outpatient treatment, reducing demand for remdesivir in some patient segments
- Biosimilar development: No current biosimilars for remdesivir approved; patent protections anticipated to hold until 2030
- Emerging therapies: Monoclonal antibody agents and oral antivirals potentially reduce remdesivir's market share
Market Drivers and Barriers
- Drivers: Ongoing COVID-19 waves, hospital adoption, intravenous administration feasibility in hospital settings, chronic management inclusion
- Barriers: Increased use of outpatient oral formulations, high infusion costs, limited efficacy compared to newer agents, evolving treatment guidelines
Supply Chain and Manufacturing Considerations
- Complex synthesis process, reliance on supply chain stability for key intermediates, potential for price volatility if shortages occur
- Gilead's capacity expansions have aimed to meet global demand, including agreements with global suppliers
Policy and Reimbursement Impact
- U.S. CMS reimbursement policies cover remdesivir under inpatient PPS, with specific billing codes (HCPCS code: J7170)
- Potential for price negotiations to influence future reimbursements; participation in CDC procurement programs impacts domestic access
Summary
The remdesivir market remains relatively stable but faces pressure from emerging oral antivirals and updated treatment protocols. Price projections indicate a gradual decline over the next five years, stabilized around $2,000-$2,500 per course. The ongoing need for hospital-based treatment in severe COVID-19 cases sustains demand, but competition and policy changes could challenge market size and pricing.
Key Takeaways
- NDC 64950-0218 (remdesivir) has an initial treatment cost around $3,120 per course, with prices expected to decline to approximately $2,000-$2,500 in 2025.
- The U.S. remains the primary market, with demand driven by COVID-19 hospitalization rates.
- Competition from oral antivirals and biosimilar development could limitar market share and influence price trends.
- Reimbursement policies and supply chain factors sustain current demand but may constrain pricing power.
- Market stability is probable through 2025, but pricing trends and market share are susceptible to evolving treatment guidelines and new antiviral agents.
Frequently Asked Questions
1. How does remdesivir's price compare to other COVID-19 treatments?
Remdesivir’s treatment course costs approximately $3,120 initially, which is higher than oral antivirals like Paxlovid (~$530 per course), but its intravenous administration limits usage to hospitalized patients.
2. Are there plans for biosimilars for remdesivir?
No biosimilars have been approved yet; patent protections are expected until 2030, delaying biosimilar entry.
3. How will new antiviral treatments impact remdesivir's market?
Oral antivirals like Paxlovid and Molnupiravir are preferred for outpatient treatment, reducing remdesivir’s use outside hospitalized settings, potentially shrinking its market share.
4. What are the main factors influencing remdesivir pricing?
Pricing is influenced by supply chain stability, hospital negotiation power, treatment guidelines, and competition from newer therapies.
5. What is the outlook for remdesivir demand?
Demand will likely persist in severe cases requiring hospitalization, but overall demand could decline with the broader adoption of outpatient antivirals and evolving guidelines.
References
- Gilead Sciences. Veklury (Remdesivir) Prescribing Information. [2020]
- IQVIA. COVID-19 Treatment Market Insights and Forecasts. [2023]
- Centers for Medicare & Medicaid Services. Outpatient drug reimbursement policies. [2022]
- FDA. Approval letter for Veklury (Remdesivir). [2020]
- Deloitte. COVID-19 Impact on Pharmaceutical Pricing. [2023]
